RKVTF (Rakovina Therapeutics) Moat Score: 3/10 (As of Jul. 06, 2026)


RKVTF Rakovina Therapeutics Inc RKVTF
32 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Moat Score?

Rakovina Therapeutics RKVTF 32 Moat Score is 3 as of Jul. 06, 2026. GuruFocus rates RKVTF with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Rakovina Therapeutics ranks better than 75.48% on this metric.

Rakovina Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Rakovina Therapeutics has No Moat: Rakovina Therapeutics Inc operates in the biotech sector with potential intellectual property advantages, but it lacks market leadership, strong brand strength, and significant regulatory barriers. The company's competitive position is very weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rakovina Therapeutics might have No Moat - Very weak/transient advantages.

Rakovina Therapeutics  (OTCPK:RKVTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rakovina Therapeutics Moat Score Related Terms

RKVTF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Rakovina Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Moat Score falls into.


RKVTF
32GF Score
Rakovina Therapeutics Inc RKVTF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Rakovina Therapeutics (RKVTF) has a Moat Score of 3 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rakovina Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Rakovina Therapeutics' Moat Score too high?
Rakovina Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Rakovina Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Rakovina Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rakovina Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rakovina Therapeutics ranks #342 out of 1395 companies for Moat Score. This places Rakovina Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Rakovina Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rakovina Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rakovina Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Rakovina Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current Moat Score is 3 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
32GF Score

Get the complete analysis for RKVTF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price